Arcturus Therapeutics

Arcturus Therapeutics Holdings, Inc. develops pharmaceuticals. It is a clinical-stage mRNA medicines and vaccines company, which focuses on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The firm's products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Arcturus Therapeutics reports robust earnings and advances in mRNA pipeline

Arcturus Therapeutics delivered strong financial results and showcased progress across key strategic areas
The company's collaborations, advancements in RNA technology, and clinical trial milestones position it for future success
While facing competition and challenges, Arcturus has opportunities to leverage its strengths and drive growth in the mRNA space

Arcturus reports strong Q1 earnings, advances COVID vaccine development

Arcturus Therapeutics demonstrated robust financial performance, progress in COVID-19 vaccine development, and advancements in mRNA therapeutics.
While facing challenges in drug safety and regulatory approvals, the company is well-positioned to capitalize on opportunities for expansion and innovation.
Strategic collaborations and a strong cash position enhance Arcturus' competitive edge and potential for sustained growth in the biopharmaceutical sector.

Arcturus Therapeutics reports Q2 results, advances key programs with CSL

Arcturus Therapeutics showcased financial resilience with a strong cash position and promising program advancements in Q2 2023.
While facing challenges such as high operating expenses and uncertainties in clinical trials, the company is leveraging opportunities for market expansion and program advancement.
Collaboration with CSL and progress on key programs like ARCT-154 and ARCT-810 position Arcturus for continued growth and innovation in the biopharmaceutical space.
Investors can look forward to data releases, program updates, and potential market expansions as Arcturus navigates financial challenges and capitalizes on growth opportunities.

Arcturus Therapeutics excels in Q3 with promising pipeline advancements

Arcturus Therapeutics demonstrated strong financial performance, operational efficiency, and clinical progress in key pipeline candidates, positioning the company for future growth and success.
The company's technological strengths, diverse pipeline, and strategic partnerships underscore its innovation and commitment to addressing unmet medical needs, enhancing market competitiveness.
While facing challenges in regulatory approvals and study outcomes, Arcturus has opportunities to expand its product portfolio, leverage mRNA technology advantages, and drive market growth through strategic planning.
Overall, Arcturus' Q3 earnings call highlights a balanced outlook of financial stability, clinical advancements, and strategic opportunities, signaling a positive trajectory for the company's future.

Arcturus Therapeutics reports mixed financials but strong vaccine pipeline

Arcturus Therapeutics faces financial challenges with expenses exceeding revenues, but maintains a stable cash runway and strong pipeline of vaccine programs
The company's focus on vaccine development for various diseases and mRNA therapeutics showcases promising strengths and diversification in its product offerings
Opportunities in the Japanese market, upcoming Phase II study results, and operational advancements present avenues for growth and value creation for Arcturus

Arcturus reports Q1 results, eyes growth through clinical progress

Arcturus Therapeutics reported mixed financial results in Q1 2024 but remains well-positioned with strong cash reserves and ongoing clinical advancements.
Challenges include managing expenses, revenue variability, and timing uncertainties in future guidance tied to Kostaive revenues.
However, opportunities lie in positive trial outcomes, potential milestone payments, and strategic alignment with global health initiatives.
Overall, Arcturus shows promise in its financial stability, clinical progress, and strategic positioning for future growth and innovation.

Arcturus Therapeutics excels in Q2 2024, poised for mRNA innovation

Arcturus Therapeutics demonstrated strong financial performance and progress in key programs, supported by a solid cash position and strategic collaborations.
While facing challenges such as cost management and regulatory complexities, the company is well-positioned to leverage opportunities in mRNA therapeutics and vaccine development.
Overall, Arcturus shows promise in advancing its pipeline and capturing growth opportunities in the evolving biopharmaceutical landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Investors are applauding Arcturus' collaboration with CSL.

Why Arcturus Therapeutics Stock Is Skyrocketing Today

A strategic collaboration has today's traders talking about Arcturus Therapeutics (NASDAQ: ARCT ) and CSL (OTCMKTS: CSLLY ). Reportedly, the two companies will work together on mRNA technology for a wide variety of applications.

Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today?

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced a strategic collaboration with CSL Seqirus, a global vaccine leader, for the research, development, manufacture, and global commercialization of vaccines.

Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines

CSL Ltd

KING OF PRUSSIA, Pa. , Nov. 1, 2022 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings Inc ("Arcturus Therapeutics") to access their late stage self-amplifying mRNA (sa-mRNA) vaccine platform technology.

CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended September 30, 2022 after the market close on Wednesday, November 9 and will also host a conference call and webcast a

Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences. Jefferies Cell and Genetic Medicine Summit (Attending) Thursday – Friday, September 29 – 30, 2022 Cantor Neurology &am

Arcturus Therapeutics to Attend the Following Investor Conferences

Brookdale Senior Living

IAMGOLD

Kratos Defense & Security Solutions

Ranger Oil Corp

NuScale Power Corp

Warby Parker

With several worrying developments domestically and internationally, many investors chose to rush for the exits, though a brave few may have opportunities in small-cap stocks to buy on the dip. Tethered to small-capitalization companies, these market ideas don't always grab the spotlight.

7 Small-Cap Stocks to Buy on the Dip or You'll Be Kicking Yourself Later

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it has obtained an award for up to $63.2 million from the Biomedical Advanced Research and Development Authority (BARDA). The award provides $63.2 million over three years to su

Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, “Arcturus Therapeutics”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced updated data from its ongoing ARCT-154 booster clinical trial. The new results demonstrate broad neutralizing antibody response against Omicron variants of c

Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine

Acrturus Therapeutics Holdings Inc. Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Joseph Payne - President and Chief Executive Officer Andrew Sassine - Chief Financial Officer Pad Chivukula - Chief Scientifc Officer and Chief Operating Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Nick Abbott - Wells Fargo Kumaraguru Raja - Brookline Capital Markets Yale Jen - Laidlaw and Company Yigal Nochomovitz - Citigroup Steven Seedhouse - Raymond James Operator Good day and welcome to the Arcturus Therapeutics Second Quarter 2022 Financial Update and Pipeline Progress Call. Today's conference is being recorded.

Acrturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q2 2022 Results - Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, “Arcturus Therapeutics”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the second quarter ended June 30, 2022, and provided corporate updates. “Arcturus continues to demonstrate increasing value of our

Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2022 after the market close on Tuesday, August 9 and will also host a conference call and webcast at 4:30 pm

Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

An EUA for ARCT-154 as a COVID-19 vaccine in Vietnam has been submitted, with expected approval in 2022. A phase 2 study using ARCT-810 as a treatment option for patients with OTC deficiency is expected to start in mid-2022; results are then expected 2nd half of 2022.

Arcturus: Potential Based On Rare Disease Therapy ARCT-810

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q1 2022 Results Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Deepankar Roy - Senior Director, Investor Relations Joseph Payne - President and Chief Executive Officer Andrew Sassine - Chief Financial Officer Pad Chivukula - Chief Scientific Officer and Chief Operating Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Evan Wang - Guggenheim Partners Nick Abbott - Wells Fargo Securities Yigal Nochomovitz – Citigroup Kumaraguru Raja - Brookline Capital Markets Steven Seedhouse - Raymond James & Associates Thomas Yip - H.C. Wainwright & Co. Operator Good day.

Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q1 2022 Results - Earnings Call Transcript

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -50.39% and 60.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress

Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) provided updated data from its Phase 1/2 booster clinical trial showing the durability of antibody response with ARCT-154 for at least three months after a low-dose (5 mcg) booster. The study also exhibited that booster vaccination generated.

Arcturus Reports Three-Month Durability Results From ARCT-154 COVID-19 Booster Trial

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial

CORRECTING and REPLACING GRAPHIC Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial

Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022

Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022

Phase 3 pivotal study succeeds in endpoints using ARCT-154 for Covid-19; Emergency Use Authorization submitted to Vietnam with possible approval for use in coming weeks/months. Ability to expand ARCT-154 in the Covid-19 booster treatment market space; Company already received feedback from several regulators for such a pivotal booster study for Covid-19.

Arcturus: Biotech With Great Potential In Covid-19 Vaccine Space

Shares of Acturus Therapeutics Holdings Inc. ARCT, -1.43% were down 2.3% in trading on Wednesday after the company said two doses of its experimental COVID-19 vaccine had an efficacy rate of 55% against infection. The Phase 3 clinical trial evaluated the vaccine in 19,000 people in Vietnam; it also found that the investigational shot had an efficacy rate of 95% against severe disease.

Raymond James analyst doesn't expect Arcturus' COVID-19 vaccine to be authorized in the U.S.

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) shared topline data from an ongoing Phase 1/2/3 trial evaluating the ARCT-154, a self-amplifying mRNA COVID-19 vaccine candidate. Results from the efficacy analysis have been submitted to the Vietnam Ministry of Health by Vinbiocare.

Arcturus' COVID-19 Vaccine Candidate Meets Primary Goal In Vietnam Study

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study

News for Arcturus Therapeutics Stock (ARCT)